Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NSAID Panel Could Give Naproxen Labeling Edge

This article was originally published in The Tan Sheet

Executive Summary

FDA’s Arthritis and Drug Safety and Risk Management advisory committees on Feb. 10-11 will examine cardiovascular risk data for non-steroidal anti-inflammatory drugs, including meta-analyses indicating naproxen could have a better safety profile than other OTC ingredients ibuprofen and ketoprofen.

You may also be interested in...



NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim

Does wide public health concern warrant flexibility in regulatory standards for safety claims? An advisory panel on cardiovascular risk of NSAIDs spotlights the dual challenge of accurately determining drug risks and communicating risks in informative way.

NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim

Does wide public health concern warrant flexibility in regulatory standards for safety claims? An advisory panel on cardiovascular risk of NSAIDs spotlights the dual challenge of accurately determining drug risks and communicating risks in informative way.

OTC NSAIDs Need Additional Label Warnings – FDA Advisory Panel

Labels for over-the-counter NSAIDS need additional information about potential risks, panel members in a joint meeting of FDA’s Arthritis and Drug Safety and Risk Management advisory committees say. Data do not show naproxen has a lower CV thrombotic event risk compared to other NSAIDs, they say.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel